| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Transtech Medical Solutions, LLC is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
International Health Management Inc is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Prestige Care is a Washington-based provider of senior living and long-term care in the Western region of the United States. Founded in 1985, Prestige`s care philosophy is rooted in a set of shared core values that deliver on a promise to provide unmatched quality care, led by a compassionate heart. Across the company, Prestige team members strive to personally touch lives, guided by the four pillars of our core values: respect, integrity, commitment and trust. Prestige`s core values are instilled by the legacy of Sarah Delamarter, a pioneer in the long-term care industry. Today, Sarah`s legacy lives on through Prestige Care Inc, which includes 72 senior care communities across eight states. Prestige Care is a complete senior services organization, which provides Nursing and Rehabilitation services, Memory Care, and Assisted Living and Retirement Services. Prestige communities` commitment to excellence has been recognized by the American Healthcare Association with multiple Bronze and Silver quality care awards. In 2012 Prestige received the Innovators Award from the International Council on Active Aging® (ICAA), for its Expressions Memory Care program. Expressions is a life-affirming, activity-rich residential program for individuals with Alzheimer`s disease and other forms of dementia who seek community-based care to help alleviate the affects of the disease for patients and their families.